Israel’s Gamida Cell's NiCord therapy for patients with high risk blood cancers has been given a breakthrough therapy designation by the FDA. The breakthrough therapy designation (BTD ...
NiCord may provide a single unit of expanded cord blood with clinical results comparable to those seen in a double cord setting. A phase III study is scheduled to start at the end of 2015.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback